Paeds · haematology-oncology-and-transfusion
Long-term follow-up and late effects of childhood cancer
Also known as Childhood cancer survivorship · Late effects of childhood cancer therapy · Long-term follow-up after childhood cancer · Paediatric cancer survivor · Anthracycline cardiomyopathy · Radiation-associated second malignancy · Endocrine late effects of cancer therapy · Cancer survivorship transition
Fellowship guide to the long-term follow-up and late effects of childhood cancer. Covers the survivor as the success story of modern oncology with over eighty percent five-year survival and the simultaneous burden of the chronic health conditions that follow the cure, the organ-system late effects of endocrine failure with growth hormone deficiency and hypothyroidism, anthracycline cardiomyopathy, subsequent malignancies, neurocognitive decline and infertility, the treatment-summary-driven and risk-stratified lifelong surveillance built on the Children's Oncology Group and the Dutch Late Effects guidelines, the surveillance for breast cancer after chest radiation and cardiomyopathy after anthracycline exposure, and the structured transition of the adolescent survivor to the adult late-effects service.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A childhood cancer survivor with a cumulative anthracycline dose of two hundred and fifty milligrams per square metre or more is at high risk of cardiomyopathy and needs lifelong echocardiographic surveillance, because the cardiac dysfunction can be silent for years before the heart failure declares
- A woman who received chest radiation of twenty gray or more during childhood needs annual mammography and breast magnetic resonance imaging from eight years after the radiation or at age twenty five, whichever occurs later, because the breast cancer risk approaches that of a BRCA carrier
- A survivor with a cranial radiation exposure of eighteen gray or more is at high risk of growth hormone deficiency and a second central nervous system tumour, and the growth failure and the new neurological symptom are not to be attributed to the original treatment without assessment
- A survivor presenting with acute severe headache, a new focal deficit or back pain may have a second central nervous system malignancy or a secondary leukaemia, and the late effect is not the default diagnosis until the new malignancy is excluded
- A survivor with unexplained fatigue, weight loss, hypotension or hyponatraemia may have adrenal insufficiency from hypothalamic-pituitary damage after cranial radiation, and the adrenal crisis is a preventable death if the cortisol deficiency is recognised
- Poor adherence to the surveillance is itself the red flag, because most survivors do not receive risk-based follow-up and the preventable late effects are the ones the surveillance was designed to catch
Life stages
Care settings
Clinical exam formats
Board mappings
- Recognises that over eighty percent of children diagnosed with cancer now survive five years and that the late effects of the therapy are the price of the cure
- Names the major organ-system late effects: endocrine failure, anthracycline cardiomyopathy, subsequent malignancy, neurocognitive decline and infertility
- Identifies the treatment summary as the foundation of the risk-based lifelong surveillance of the childhood cancer survivor
- Explains the dose-dependent anthracycline cardiomyopathy with the cumulative doxorubicin-equivalent dose of two hundred and fifty milligrams per square metre as the conventional high-risk threshold and the lifelong echocardiographic surveillance it mandates
- Builds the risk-stratified surveillance plan using the treatment exposures against the Children's Oncology Group and the Dutch Late Effects guidelines, including the breast magnetic resonance imaging after chest radiation and the echocardiography after anthracycline exposure
- Coordinates the multidisciplinary survivorship team across endocrinology, cardiology, neuropsychology, reproductive medicine and the primary care, and the structured transition of the adolescent to the adult late-effects service
- Over eighty percent of children diagnosed with cancer now survive five years, and the majority carry at least one chronic health condition by adulthood
- A cumulative anthracycline dose of two hundred and fifty milligrams per square metre or more is high risk for cardiomyopathy and mandates lifelong echocardiographic surveillance
- A woman who received chest radiation of twenty gray or more needs annual mammography and breast magnetic resonance imaging from eight years after the radiation or at age twenty five, whichever occurs later
- Synthesises the long-case survivor into a treatment-summary-driven and risk-stratified surveillance plan across the endocrine, cardiac, oncologic and neurocognitive domains
- Counsels the adolescent survivor and the family on the fertility implications of the gonadotoxic exposure, the surveillance for the second malignancy and the transition to the adult late-effects service
- Recognises the acute presentations of the late effects, including the decompensated anthracycline cardiomyopathy and the adrenal crisis from the hypothalamic-pituitary failure
- Level 1: Recognition that the childhood cancer survivor carries a lifelong burden of chronic health conditions that follow the cure
- Level 2: Application of the treatment summary and the risk-based surveillance against the Children's Oncology Group guidelines for the common late effects
- Level 3: Coordination of the multidisciplinary survivorship care and the structured transition of the adolescent to the adult late-effects service
- The major organ-system late effects of childhood cancer therapy and their treatment-exposure correlates
- The dose-dependent anthracycline cardiomyopathy and the radiation-associated second malignancy as the two highest-yield late effects
- The risk-based surveillance framework built on the treatment summary and the Children's Oncology Group guidelines
- Structured assessment of the childhood cancer survivor with the growth and pubertal staging, the cardiac and thyroid examination and the skin examination for the second malignancy
- Communication of the surveillance plan, the fertility implications and the transition to the adult service to the adolescent survivor and the family
- Recognition of the acute decompensation of a late effect, including the heart failure and the adrenal crisis
- The childhood cancer survivor as the paradigm of the chronic multisystem condition in the paediatric follow-up
- The treatment-summary-driven and risk-based surveillance for the endocrine, cardiac and oncologic late effects
- The structured transition of the adolescent survivor to the adult late-effects care
- Recognition that the majority of childhood cancer survivors carry chronic health conditions and that the surveillance is risk-based and lifelong
- Application of the treatment summary to the surveillance plan for the anthracycline cardiomyopathy, the endocrine failure and the second malignancy
- Coordination of the multidisciplinary survivorship care and the transition of the adolescent to the adult service
- Canadian approach to the risk-based lifelong surveillance of the childhood cancer survivor
- The endocrine and the cardiac surveillance thresholds and the second-malignancy screening built on the treatment summary
- The structured transition of the adolescent survivor to the adult late-effects clinic
Overview & Definition
A young woman walks into the general paediatric clinic at the age of twenty-two, fifteen years after she received chemotherapy and chest radiation for a Hodgkin lymphoma as a child, and the question that frames her whole visit is not whether the lymphoma will return but what the treatment that cured her is now doing to her heart, her breasts, her thyroid and her fertility. The long-term follow-up of the childhood cancer survivor is the discipline that grew out of the single greatest success of modern paediatric oncology, which is that over eighty percent of children diagnosed with cancer in the high-income countries now survive five years from the diagnosis. The survival that was unimaginable sixty years ago, when fewer than one in ten children with cancer survived, has created a growing population of survivors whose cure was bought at the price of the late effects of the surgery, the radiotherapy and the chemotherapy that saved them. [1][2]
A late effect is defined as a chronic or a late-occurring physical or psychological complication that persists or emerges after the cancer treatment has ended, and it is the direct consequence of the exposure to the cytotoxic therapy and not of the cancer itself. The late effects are distinguished from the long-term effects, which are present during or immediately after the treatment, by their delayed onset, because many declare themselves years or decades after the exposure. The anthracycline cardiomyopathy, the radiation-associated second malignancy, the growth hormone deficiency and the premature ovarian failure are the archetypes, and each follows the specific treatment exposure with a latency that can stretch across the decades of the survivor's adult life. [3][5]
The scale of the burden is what gives the topic its weight, and the single most cited figure is that nearly three quarters of the adult survivors of childhood cancer carry at least one chronic health condition, and that over forty percent carry a condition that is severe, life-threatening or disabling. The cumulative incidence of the chronic conditions rises with the time from the diagnosis, so that longer survivor lives the more likely the late effect, and the survivor who reaches the age of fifty carries the health profile of a person a generation older. The late effects are therefore not the rare complications of a fortunate few but the expected companion of the cure, and the task of the clinician is to anticipate, to detect and to mitigate them across the survivor's life. [1]
The framework that organises the whole topic is the link between the treatment exposure and the late effect, because every surveillance decision is driven by what the child received. The anthracycline dose predicts the cardiomyopathy, the chest radiation field and dose predict the breast cancer, the cranial radiation predicts the neurocognitive decline and the growth hormone deficiency, the alkylating agent dose predicts the gonadal failure, and the platinum compound predicts the ototoxicity. The fellow who holds these exposure-to-effect links can build the surveillance plan from the treatment summary alone, and the plan is what separates the child who is followed from the child who is lost to the late effects. [2][12]
References12ShowHide
- [1]Oeffinger KC, Mertens AC, Sklar CA Chronic health conditions in adult survivors of childhood cancer N Engl J Med, 2006.PMID 17035650
- [2]DeVine A, Landier W, Hudson MM The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review JAMA Oncol, 2025.PMID 39976936
- [3]Chemaitilly W, Cohen LE, Mostoufi-Moab S Endocrine Late Effects in Childhood Cancer Survivors J Clin Oncol, 2018.PMID 29874130
- [4]Friedman DL, Whitton J, Leisenring W Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study J Natl Cancer Inst, 2010.PMID 20634481
- [5]Leerink JM, de Baat EC, Feijen EAM Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review JACC CardioOncol, 2020.PMID 34396245
- [6]Bates JE, Howell RM, Liu Q Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study J Clin Oncol, 2019.PMID 30860946
- [7]van Iersel L, Mulder RL, Denzer C Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors Endocr Rev, 2022.PMID 34962573
- [8]Stefanski KJ, Anixt JS, Goodman P Long-Term Neurocognitive and Psychosocial Outcomes After Acute Myeloid Leukaemia: A Childhood Cancer Survivor Study Report J Natl Cancer Inst, 2021.PMID 32797189
- [9]Armstrong GT, Liu W, Leisenring W Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study J Clin Oncol, 2011.PMID 21709189
- [10]Yan AP, Chen Y, Henderson TO Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study J Clin Oncol, 2020.PMID 32142393
- [11]Fardell JE, Wakefield CE, Signorelli C Transition of childhood cancer survivors to adult care: The survivor perspective Pediatr Blood Cancer, 2017.PMID 28436208
- [12]Landier W, Bhatia S, Eshelman DA Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline J Clin Oncol, 2004.PMID 15576413